Visit COVID-19 resources

[Skip to Content]

Clinical Guidance

Ophthalmic Safety Alert – Diabetic control and safe cataract surgery

May 01
2018

The College has received queries from members to clarify whether there is a specific cut off for glycaemic control, either measured via HbA1C or a blood glucose level on the day, beyond which it is unsafe to proceed with cataract surgery. There is anecdotal evidence of cataract surgery cases being cancelled for surgery if their

  • 1 May 2018

Ophthalmic Safety Alert – intracameral cefuroxime

May 01
2018

There are a range of cefuroxime preparations currently in use for the prevention of endophthalmitis in intraocular surgery. There are two licensed versions, Aprokam (Thea Pharmaceuticals) and  Ximaract (from Bausch & Lomb), both available as a  50mg powder and diluent solution for injection.  Also used are unlicensed prefilled syringes, of which some are compliant with

  • 1 May 2018

Ophthalmic Safety Alert – detachment of cannulas during ophthalmic surgery

Apr 17
2018

The NHS Improvement national patient safety team have informed the College of the continued trend of incidents involving issues with detachment of cannulas during ophthalmic surgery (cannula-associated ocular injury, COI). The cannula is usually attached to either a saline or a viscoelastic syringe. The combination of a small lumen and plunger pressure can result in

  • 17 April 2018

Correct IOL implantation in cataract surgery – quality standard

Mar 22
2018

The insertion of wrong intraocular lenses (IOLs) in cataract surgery is the commonest cause of surgical never events in recent years. The College has been working with NHS England and NHS Improvement (NHSI) to try to improve the situation, providing amendments to the new Never Event List and Frameworks and supporting the Healthcare Safety Investigation

  • 22 March 2018

RCOphth guideline: Hydroxychloroquine and Chloroquine Retinopathy: NEW screening recommendations February 2018

Mar 02
2018

The new guideline on screening for hydroxychloroquine and chloroquine retinopathy is written in response to evidence from the United States that shows that hydroxychloroquine retinopathy is more common than previously recognised. Implementation of the guideline’s recommendations will prevent iatrogenic visual loss. The new guideline also makes recommendations regarding the techniques and timing of baseline and

  • 2 March 2018